The effect of changing the C-4 substituent of 3,3-diethyl-1-[(benzylamino)carbonyl]-2-azetidinone on inhibition of HLE and in a model of HLE-induced lung damage in hamsters was explored. Substituents at this position do not appear to interact strongly with HLE with the most potent compounds having k(obs)/[I] = 6900 M-1 s-1. However, substituents at this position had a marked effect on in vivo activity. The greatest oral activity in the lung hemorrhage assay was achieved with C-4 aryl carboxylic acid ethers (60-85% inhibition at 30 mg/kg po). Based upon the established mechanism of inhibition by these compounds, the C-4 substituent would be released, and therefore, the pharmacological potential of these C-4 substituents was of considerable concern. Fortunately, compounds containing 4-hydroxybenzoic acid and 4-hydroxyphenylacetic acid ethers at C-4 were among the most active analogs. These phenolic acids are also found as urinary metabolites in healthy humans. Other heteroaryls at C-4 were also orally active in this model despite relatively modest enzyme activity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jm00058a015 | DOI Listing |
Bull Environ Contam Toxicol
January 2025
College of Marine Science, South China Agricultural University, Guangzhou, 510642, China.
Sediment cores were collected from the nearshore to bay mouth region in Daya Bay, aiming to describe the historical patterns of heavy metals deposition in the sediment. During the last 40 years, the heavy metals exhibited significant different deposition behaviors in the sediment, in which As, Zn, Cr were more enriched and contributed to metals pollution in this area. Moreover, heavy metals deposition exhibited completely opposite behaviors from the nearshore to bay mouth region.
View Article and Find Full Text PDFClin Cancer Res
January 2025
The Wistar Institute, Philadelphia, PA, United States.
Purpose: A first-in-human phase one study was conducted in nasopharyngeal carcinoma (NPC) patients to assess the safety and tolerability of VK-2019, a small molecule selective inhibitor of Epstein-Barr virus Nuclear Antigen 1 (EBNA1).
Patients And Methods: Pharmacokinetic and pharmacodynamic studies, including circulating tumor EBV DNA plasma levels, were performed. Twenty-three patients received VK-2019 orally once daily at doses ranging from 60 to 1800 mg using an accelerated titration design, with cohort expansion at 1800 mg.
Objective: To analyze the dynamics of the condition of the mucous membrane in patients with metabolic syndrome at the stage of preparation for dental prosthetics using dental implants.
Material And Methods: 255 patients (151 women and 104 men) aged from 35 to 65 years were examined. 3 groups were formed: 2 study groups and a comparison group.
The Aim Of The Study: To study the expression of NOD receptors of immunotropic periodontal tissue cells in patients with aggressive periodontitis before and after complex treatment.
Materials And Methods: 15 patients aged 22 to 36 years with aggressive periodontitis were examined before and 21 days after the start of complex treatment. 15 patients with fibroids of the oral mucosa without signs of inflammation served as controls.
PNAS Nexus
January 2025
Department of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
We identified a 5-fluoro-benzothiazole-containing small molecule, TKB272, through fluorine-scanning of the benzothiazole moiety, which more potently inhibits the enzymatic activity of SARS-CoV-2's main protease (M) and more effectively blocks the infectivity and replication of all SARS-CoV-2 strains examined including Omicron variants such as SARS-CoV-2 and SARS-CoV-2 than two M inhibitors: nirmatrelvir and ensitrelvir. Notably, the administration of ritonavir-boosted nirmatrelvir and ensitrelvir causes drug-drug interactions warranting cautions due to their CYP3A4 inhibition, thereby limiting their clinical utility. When orally administered, TKB272 blocked SARS-CoV-2 replication without ritonavir in B6.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!